GlaxoSmithKline | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-GSK plc(4.5%)
GlaxoSmithKline | 6-K: Transaction Notification
GlaxoSmithKline | F-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers
GlaxoSmithKline | 6-K: GlaxoSmithKline releases notice of 2024 Annual General Meeting of Shareholders
GlaxoSmithKline | 6-K: We Transferred 27.8 Million Ordinary Shares of 31 1/4 Pence Each Held in Treasury to the Company's Depositary, Jpmorgan Chase Bank, Na
GlaxoSmithKline | 6-K: Transaction Notification
GlaxoSmithKline | 6-K: Positive Ruby Phase Iii Data Show Potential for Jemperli (Dostarlimab) Combinations in More Patients with Primary Advanced or Recurrent Endometrial Cancer
GlaxoSmithKline | 6-K: Transaction Notification
GlaxoSmithKline | 6-K: Dr Hal Dietz Has Been Appointed a Member of the Nominations & Corporate Governance Committee
GlaxoSmithKline | 6-K: Gsk Announces Positive Results from Dreamm-8 Phase Iii Trial for Blenrep Versus Standard of Care Combination in Relapsed/Refractory Multiple Myeloma
GlaxoSmithKline | 6-K: Viiv Healthcare Announces Interim Data at Croi Indicating Superior Efficacy of Long-Acting Injectable Hiv Treatment Cabenuva (Cabotegravir + Rilpivirine) Compared to Daily Oral Therapy in Individuals Living with Hiv Who Have Adheren
GlaxoSmithKline | 6-K: Glaxosmithkline 2023 Annual Report on Form 20-F
GlaxoSmithKline | IRANNOTICE: IRANNOTICE
GlaxoSmithKline | 20-F: Registration statement / Annual report / Transition report
GlaxoSmithKline | 6-K: Viiv Healthcare Presents Phase I Clinical Trial Findings of a Cabotegravir Long-Acting Injectable Investigational Formulation Allowing at Least Four Months Between Doses
GlaxoSmithKline | 6-K: Total Voting Rights and Capital
GlaxoSmithKline | 6-K: Publication of Annual Report 2023
GlaxoSmithKline | 6-K: GlaxoSmithKline Announces Dr Jeannie Lee to Join the Board as Non-executive Director
GlaxoSmithKline | 6-K: Gsk Reaches Confidential Settlement with Boyd/Steenvoord in Zantac Litigation
GlaxoSmithKline | 6-K: Transaction Notification
No Data